Bristol-Myers Squibb Company (BMY) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 75
- Profitability 75
- Business Quality 80
- Balance Sheet 55
- Cash Flow 60
Why this rating?
Health 72/100 — High Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Bristol-Myers Squibb Company (BMY) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates Bristol-Myers Squibb Company 72/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Moderate
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 14.25
- Forward P/E 9.86
- PEG 2.5
- EV/Revenue 3.47
Profitability
- Revenue Growth 5.7%
- Gross Margin 71.7%
- Operating Margin 34.4%
- Net Margin 18.9%
- ROE 46.6%
Financial strength
- Cash $11.07B
- Debt $45.05B
- Net Cash $-33.99B
- Free Cash Flow $12.85B
- Current Ratio 1.53
Similar companies
Peers in Drug Manufacturers - General, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Eli Lilly and Company Drug Manufacturers - General LLY$1,123.91 86 Health 86 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- AstraZeneca PLC Drug Manufacturers - General AZN$160.04 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Gilead Sciences, Inc. Drug Manufacturers - General GILD$146.64 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Biogen Inc. Drug Manufacturers - General BIIB$212.50 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- AbbVie Inc. Drug Manufacturers - General ABBV$248.78 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Johnson & Johnson Drug Manufacturers - General JNJ$269.12 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Pfizer Inc. Drug Manufacturers - General PFE$27.79 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Amgen Inc. Drug Manufacturers - General AMGN$393.17 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Bristol-Myers Squibb Company (BMY).